Skip to main content

Arbutus Biopharma Corp(ABUS-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low4.40
Day High4.48
Open:4.46
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Tipranks
Arbutus Biopharma Gains FDA Fast Track for Imdusiran
GlobeNewswire
Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B
Tipranks
Arbutus Boosted by $2.25 Billion LNP Settlement and Hepatitis B Trial Progress
GlobeNewswire
Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
Tipranks
Arbutus Biopharma Reaches Transformative Global Settlement With Moderna
GlobeNewswire
Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna
GlobeNewswire
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
Tipranks
Court Narrows Moderna Defenses in Arbutus Patent Dispute
Tipranks
Arbutus Biopharma Secures Mixed Ruling in Moderna Patent Case
Tipranks
Arbutus Biopharma Faces EPO Revocation in Moderna Dispute
Tipranks
Arbutus Biopharma CEO Discusses Lawsuits Over LNP Technology
Tipranks
Arbutus Biopharma Reports Q3 2025 Financial Results
Tipranks
Arbutus Biopharma Reports Strong Q3 Financial Results
GlobeNewswire
Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Tipranks
Arbutus Biopharma’s Long-Term Hepatitis B Study: A Potential Game-Changer for Investors
Tipranks
Arbutus Biopharma Showcases Data at Liver Meeting 2025
GlobeNewswire
Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025
Tipranks
Arbutus Biopharma’s Patent Ruling in Pfizer Lawsuit
Motley Fool
Arbutus (ABUS) Q2 Revenue Surges 529%
GlobeNewswire
Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus
GlobeNewswire
Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025
GlobeNewswire
Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025
GlobeNewswire
Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
GlobeNewswire
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
GlobeNewswire
Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO
GlobeNewswire
Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat
GlobeNewswire
Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon
GlobeNewswire
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
GlobeNewswire
Arbutus to Present at Jefferies London Healthcare Conference
GlobeNewswire
Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update

Profile

Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection. The Company's products include TKM-HBV, Cyclophilin Inhibitor-OCB-030, TLR9 Agonist (CYT-003), Capsid Assembly Inhibitors, Surface Antigen Secretion Inhibitors, STING Agonists, cccDNA Formation Inhibitors, cccDNA Epigenetic Modifiers, TKM-PLK1, GI-NET and ACC, HCC, TKM-Ebola, TKM-Ebola-Guinea, TKM-Marburg, TKM-HTG and TKM-ALDH which are in different clinical trial stage. Arbutus Biopharma Corp, formerly known as Tekmira Pharmaceuticals Corporation, is headquartered in Vancouver, BC.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.